ROIVANT SCIENCES LTD. Operating Lease Cost
ROIVANT SCIENCES LTD. (ROIV) reported Operating Lease Cost of $16.02 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-05-20
- ROIVANT SCIENCES LTD. operating lease, cost for fiscal 2026 was $16.02M, a 37.75% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. operating lease, cost for fiscal 2025 was $11.63M, a 9.24% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. operating lease, cost for fiscal 2024 was $10.65M, a 2.12% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. operating lease, cost for fiscal 2023 was $10.88M, a 20.29% decline from fiscal 2022.
| Period end | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|
| 2026-03-31 | $16.02M 10-K · filed 2026-05-20 | |
| 2025-03-31 | $11.63M 10-K · filed 2026-05-20 | |
| 2024-03-31 | $10.65M 10-K · filed 2026-05-20 | $11.83M 10-K · filed 2024-05-30 |
| 2023-03-31 | $10.88M 10-K · filed 2025-05-29 | $12.04M 10-K · filed 2023-06-28 |
| 2022-03-31 | $13.65M 10-K · filed 2023-06-28 | |
| 2021-03-31 | $11.93M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |